Q2042 Tisagenlecleucel car-pos t

Tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose

• Medicare coverage: Carrier judgment
• Status: active (July 2026 file)